Scinai Immunotherapeutics earnings were -$4.8M for the trailing 12 months ending Dec 31, 2024, with -100% growth year over year. The latest SCNI earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$11.8M, down 213.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, SCNI reported annual earnings of -$4.8M, with -173.8% growth.
SCNI past earnings growth
How has SCNI's earnings growth performed historically?
Scinai Immunotherapeutics Earnings Reports & History FAQ
What were Scinai Immunotherapeutics's earnings last quarter?
Scinai Immunotherapeutics (NASDAQ: SCNI) reported Q4 2024 earnings per share (EPS) of -$10.40, up 143.33% year over year. Total SCNI earnings for the quarter were -$11.82 million. In the same quarter last year, Scinai Immunotherapeutics's earnings per share (EPS) was $24.00.
Is Scinai Immunotherapeutics profitable or losing money?
As of the last Scinai Immunotherapeutics earnings report, Scinai Immunotherapeutics is currently losing money. Scinai Immunotherapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$4.80 million, a 173.78% decrease year over year.
What was SCNI's earnings growth in the past year?
As of Scinai Immunotherapeutics's earnings date in Q2 2025, Scinai Immunotherapeutics's earnings has grown -100% year over year. This is 111.53 percentage points lower than the US Biotechnology industry earnings growth rate of 11.53%. SCNI earnings in the past year totalled -$4.80 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.